congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Dato-DXd
ISPOR 2024 | May 5-8, 2024
Estimating meaningful change thresholds for EORTC scales in a phase 3 trial in participants with inoperable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
Poster
Pexidartinib
ISPOR 2024 | May 5-8, 2024
Health-related quality of life from a phase 4 global clinical study to
evaluate discontinuation and rechallenge of pexidartinib in patients with
tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
Poster
Other/Multi
ISPOR 2024 | May 5-8, 2024
Healthcare resource use and costs of care in HR+/HER2- metastatic breast cancer: A retrospective US claims data study
Poster
T-DXd
ISPOR 2024 | May 5-8, 2024
Perceptions, experiences, and behaviors of patients and their caregivers with gastric and gastroesophageal junction cancer treated with or without trastuzumab deruxtecan in the United States
Poster
Pexidartinib
ISPOR 2024 | May 5-8, 2024
Real-world experience of patients newly initiated on pexidartinib
for tenosynovial giant cell tumor (TGCT)